Clearsight Advises Ducker Holdings on the Divestiture of Versalinx to Questex

Clearsight Advisors, Inc. (“Clearsight”) is excited to share another successful transaction in its Life Sciences and Information Services practice. Clearsight served as the exclusive financial advisor to Ducker Holdings (“The “firm” or “Ducker Holdings”), a portfolio company of Boathouse Capital LP (“Boathouse Capital”) on the divestiture of Versalinx (“The Company” or “Versalinx”) to Questex, a portfolio company of MidOcean Partners.

Versalinx, previously acquired by Ducker Holdings in 2018, is a global provider of B2B events in the pharmaceutical industry with a specialized focus on research insights and competitive intelligence. Versalinx has built a reputation for connecting senior leaders and decision-makers across the U.S. and Europe through meaningful, content-rich environments that foster collaboration and innovation across the pharmaceutical and life sciences sectors.

Questex, a leading information and events provider in the healthcare and life sciences sector, will leverage Versalinx’s deep experience in pharmaceutical events to expand its life sciences portfolio. The acquisition supports Questex’s growth strategy in fast-evolving, high-growth industries and further strengthens its global healthcare and life sciences platform, enabling broader audience access and helping customers reach new markets more effectively.

Bill Dyer, Managing Partner of Boathouse Capital, commented on the transaction, “Building scale is a key driver of value and growth for established companies. This divestiture expands Versalinx’s reach and offerings to better serve clients. We’re grateful to Clearsight for their strategic guidance and expertise throughout the process to help guide Versalinx into its next chapter of growth.”

“This transaction reflects the continued demand for specialized, high-impact engagement platforms in the life sciences sector. Versalinx’s global footprint and pharma-focused expertise make it a valuable asset in a rapidly evolving landscape,” remarked Joel Kallett, Clearsight Co-Founder and Managing Director.

Clearsight Managing Director Stephen Shankman said, “Versalinx has built a differentiated platform in the life sciences and pharmaceutical events space focused on competitive intelligence, and we are proud to have supported Ducker Holdings and Boathouse Capital in this strategic transaction. We believe Questex is a fantastic partner to help scale Versalinx’s impact and reach global markets.”

The Clearsight deal team included Joel Kallett, Stephen Shankman, Tory Steel, Conor Sokolowsky, and William Trukenbrod.